Presepsin teardown – pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis by Papp, Mária et al.
Papp M Presepsin in cirrhosis 1 
 
Name of journal: World Journal of Gastroenterology 
ESPS Manuscript NO: 28276 




Presepsin teardown – pitfalls of biomarkers in the diagnosis and prognosis 
of bacterial infection in cirrhosis 
 
Papp M et al. Presepsin in cirrhosis 
 
Maria Papp#, Tamas Tornai#, Zsuzsanna Vitalis, Istvan Tornai, David Tornai, 
Tamas Dinya, Andrea Sumegi, Peter Antal-Szalmas 
 
Maria Papp, Tamas Tornai, Zsuzsanna Vitalis, Istvan Tornai, Maria Papp 
Institute of Internal Medicine, Department of Gastroenterology, University of 
Debrecen, Faculty of Medicine, Debrecen, Hungary, H-4032 Debrecen, 
Hungary 
David Tornai, Peter Antal Szalmas Department of Laboratory Medicine, 
University of Debrecen, Faculty of Medicine Debrecen, Hungary, H-4032 
Debrecen, Hungary 
Tamas Dinya Institute of Surgery, University of Debrecen, Faculty of 
Medicine, Debrecen, Hungary, H-4032 Debrecen, Hungary 
Andrea Sumegi Vascular Biology, Thrombosis and Haemostasis Research 
Group, Hungarian Academy of Sciences, Debrecen, Hungary, H-4032 
Debrecen, Hungary 
 
Author contributions: Papp M, Tornai I, Antal-Szamas P designed the study; 
Tornai T, Tornai D, Vitalis Zs, Dinya T, Sumegi A performed research; Papp 
M, Tornai T and Antal-Szalmas P analyzed data; Papp M, Tornai T and Antal-
Szalmas P wrote the manuscript.  
Papp M Presepsin in cirrhosis 2 
#These authors contributed equally to the work and both should be 
considered as first authors. 
 
Papp M Presepsin in cirrhosis 3 
Supported by János Bólyai Research Scholarship of Hungarian Academy of 
Sciences (BO/00426/11) and by the Internal Research Grant (RH/885/2013) 
of the University of Debrecen and Research Grant of National Research 
Development and Innovation Office (K115818/2015/1). 
 
Ethics approval: The study was reviewed and approved by the Hungarian 
National Review Board and the Institutional Review Board of the University 
of Debrecen. 
 
Informed consent: All study participants, or their legal guardian, provided 
informed written consent prior to study enrollment. 
 
Conflict-of-interest: Not declared. 
 
Data sharing: No additional data are available. 
 
Open-Access: This article is an open-access article which was selected by an 
in-house editor and fully peer-reviewed by external reviewers. It is 
distributed in accordance with the Creative Commons Attribution Non 
Commercial (CC BY-NC 4.0) license, which permits others to distribute, 
remix, adapt, build upon this work non-commercially, and license their 
derivative works on different terms, provided the original work is properly 




Manuscript source: Invited manuscript 
 
Correspondence to: Maria Papp, M.D., Ph.D., Institute of Internal Medicine, 
Department of Gastroenterology, University of Debrecen, Faculty of 
Medicine, Nagyerdei krt. 98, H-4032 Debrecen, Hungary, Phone/Fax: 36-52-
255-152, e-mail: papp.maria@med.unideb.hu 





Accepted:   
Article in press: 
Published online: 
 
Papp M Presepsin in cirrhosis 5 
Abstract 
AIM: Bacterial infections are frequent complications in cirrhosis with 
significant mortality. Early laboratory diagnosis is essential but challenging. 
We aimed to evaluate the diagnostic and prognostic value of presepsin in 
cirrhosis associated bacterial infections.  
 
METHODS: 216 patients with cirrhosis were enrolled. At admission, 
presence of bacterial infections and level of plasma presepsin, serum CRP and 
PCT were evaluated. Patients were followed for three months to assess the 
possible association between presepsin level and short-term mortality.  
 
RESULTS: 34.7% of patients had bacterial infection. Presepsin levels were 
significantly higher in patients with infection than without (median, 1002 vs. 
477 pg/mL, p<0.001), increasing with the severity of infection (organ 
failure[OF]Yes vs. No: 2358 vs. 710 pg/mL, p<0.001). Diagnostic accuracy of 
presepsin for severe infections was similar to PCT and superior to CRP (AUC-
ROC: 0.85, 0.85 and 0.66, respectively, p=NS for presepsin vs. PCT and p<0.01 
for presepsin vs. CRP). At the optimal cut-off value of presepsin>1206 pg/mL 
sensitivity, specificity, PPV and NPV were as follows: 87.5%, 74.5%, 61.8% 
and 92.7%. The accuracy of presepsin, however, decreased in advanced stage 
of the disease or in the presence of renal failure, most probably because of the 
significantly elevated presepsin levels in non-infected patients. 28-day 
mortality rate was higher among patients with >1277 pg/mL compared to 
those with ≤1277 pg/mL (46.9% vs. 11.6%, p<0.001). In a binary logistic 
regression analysis, however, only PCT [OR: 1.81, (95%CI: 1.09–3.01), p=0.022] 
but neither presepsin and nor CRP were independent risk factor for 28-day 
mortality after adjusting with MELD score and leukocyte count. 
 
CONCLUSION: Presepsin is a valuable new biomarker for defining severe 
infections in cirrhosis proving same efficacy as PCT. However, it is not a 
useful marker of short-term mortality.  
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Core tip: C-reactive protein (CRP) and procalcitonin (PCT) are broadly used 
in clinical practice to aid early diagnosis of bacterial infections, but they have 
limitations in cirrhosis. Additional biomarkers with enhanced accuracy are 
highly needed. Presepsin is a novel biomarker of infection and sepsis, but has 
not been assessed in cirrhosis so far. In the present study we evaluated the 
diagnostic and prognostic performance of presepsin in cirrhosis-associated 
infections in comparison with classic acute phase proteins. Presepsin 
measurement enhanced diagnostic capacity of CRP and reflected the severity 
of infections more accurately, with a similar efficacy as PCT. Advanced 
diseases stage and renal failure limited the diagnostic accuracy. The increase 
in PCT level but not in presepsin concentration was an independent predictor 
of short-term mortality during infectious episodes. 
 
List of abbreviations: 
ACLF: acute-on-chronic liver failure, AD: acute decompensation, AKI: acute 
kidney injury, APP: acute phase protein, AUC: area under the curve, BT: 
bacterial translocation, CLEIA: chemiluminescent enzyme immunoassay, CPs: 
Child-Pugh score, CRP: C-reactive protein, HCC: hepatocellular carcinoma, 
ICU: intensive care unit, IQR: interquartile range, MELD: model for end-stage 
liver disease, MW: molecular weight, NPV: negative predictive values, N.S.: 
non-significant, PCT: procalcitonin, PPV: positive predictive values, MR-
proADM: mid-regional pro-adrenomedullin, ROC: receiver operating 
characteristic, SBP: spontaneous bacterial peritonitis, sCD14-ST: presepsin 
(soluble CD14 subtype), SD: standard deviation, SIRS: systemic inflammatory 
response, SuPAR: soluble urokinase plasminogen activator receptor, UTI: 
urinary tract infection 
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INTRODUCTION 
 Infectious episodes represent particularly important causes of progression of 
liver failure and the development of liver-related complications[1]. Due to 
altered sensitivity, the end-organ damaging effect of bacterial infection is 
greater in cirrhosis and often culminates in newly developed liver and/or 
extrahepatic organ failures, which is associated with a very high short-term 
mortality rate[2,3].  
Early recognition of bacterial infections is essential, however, in the 
clinical practice their accurate identification is challenging from both the 
clinical[4] and the laboratory part[5]. In cirrhosis, usual clinical presentations 
lack up to 50% of the bacterial infections and are replaced by non-specific 
complaints or just revealed by organ dysfunctions. Due to some disease 
specific characteristics, there is an evident lack of sensitivity and specificity of 
the conventional laboratory and clinical parameters for the definition of 
systemic inflammatory response (SIRS)[6,7], which makes it difficult to 
diagnose sepsis.  
Currently C-reactive protein (CRP) and procalcitonin (PCT) are 
broadly used in the clinical practice to aid the early diagnosis of bacterial 
infection [8]. In cirrhosis, these conventional markers, however, perform 
somewhat differently in comparison with the non-cirrhotic patient 
populations for various reasons. For the first, if the main source of the 
molecule is the liver, like in the case of CRP, synthesis of the molecule is 
affected by liver failure and its severity. As a result the diagnostic accuracy of 
liver synthesised acute phase proteins (APPs) decreases in advanced stage of 
cirrhosis[9]. Moreover, peak levels can be misleading and do not indicate the 
severity of the infection adequately, since the more severe the underlying 
liver dysfunction, the lower the CRP response to bacteraemia is[10]. Secondly, 
elimination of certain molecules can be affected by renal failure and also renal 
replacement therapy. Acute kidney injury (AKI) is frequent in patients with 
cirrhosis, especially in bacterial infections[11]. While CRP has a high molecular 
weight (MW) (115-kDa) and its renal clearance is negligible[12,13], PCT is small 
with a MW of 13 kDa and renal elimination is thought to be one of the major 
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pathways for its elimination[14]. Accordingly, false or inappropriate increase 
of the PCT level was reported in end-stage renal disease patients due to the 
prolonged elimination rate[15,16]. Similarly, artificial reduction of the PCT level 
was also found after renal replacement therapy (HCO-CVVHDF). Proteins 
with MW<60 kDa is filtered by the dialysis membrane[17]. Thirdly, 
inflammatory state sustained by bacterial translocation (BT) and without 
overt infection is sufficient alone to elevate inflammatory markers to a 
significant level[5,9]. Bacterial translocation is an increasing problem with 
diseases severity[18]. 
Accordingly, data are not homogeneous about the optimal cut-off for 
either of CRP and PCT to differentiate patients with infection from those 
without[19–23]. Probably using a single threshold is not appropriate. Additional 
biomarkers are highly needed to optimize the rule in and rule out processes 
necessary for the diagnosis and also for the severity assessment of the 
infectious episodes in cirrhosis. 
Presepsin (soluble CD14 subtype, sCD14-ST) is a 13-kDa-cleavage 
product of CD14 receptor that recognizes different cell surface structure of 
both Gram-negative and positive bacteria. Presepsin in the circulation can be 
perceived as a witness of activated monocyte-macrophage in response to 
pathogens[24].  Several recent clinical studies have shown that presepsin is a 
specific and sensitive novel marker for the diagnosis of sepsis[25], for 
evaluating the severity of sepsis and for predicting the outcome[26,27]. Beyond 
sepsis, presepsin is worthy of studying in those clinical settings, where 
systemic infections are frequently associated with severe diseases course such 
in cirrhosis (acute decompensation [AD], organ failure). Contributive role of 
presepsin for the diagnosis and prognosis of cirrhosis associated bacterial 
infection has not been assessed extensively so far.  
In the present study, we aimed to assess (1) performance of presepsin 
in the diagnosis of cirrhosis associated bacterial infections in comparison with 
routinely used APPs such as CRP and PCT, (2) whether presepsin is devoid of 
the limitations of classic APPs related to cirrhosis, and (3) whether presepsin 
is able to provide prognostic information during infectious episodes in 
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cirrhosis. 
 
MATERIAL AND METHODS 
Patient population 
Two hundred and sixteen, well-characterized patients with cirrhosis 
(male/female: 118/99, age: 57.5 ± 10.3 years, disease duration: 3.9 ± 4.2 years) 
were included consecutively from our in- and outpatient Gastroenterology 
Department between May 2010 and April 2011. The diagnosis of cirrhosis was 
considered either histologically proven or considered obvious by clinical, 
biochemical and morphological criteria[28].  
 
Data collection 
The clinical and laboratory characteristics of the patients are presented 
in Table 1. Clinical data were recorded at enrolment. These concerned 
demographics, co-morbidities (including cardio- and cerebrovascular, 
respiratory, renal disorders, diabetes and extrahepatic cancers), etiology of 
cirrhosis, history and severity of liver disease, presence of hepatocellular 
carcinoma (HCC), reason for AD, clinical status of patients, and also presence, 
type and location of bacterial infection. Severity of the cirrhosis was graded 
according to liver-oriented scores (Child-Pugh score [CPs] and the model for 
end-stage liver disease [MELD])[29]. Episodes of AD were defined by acute 
development of large ascites, hepatic encephalopathy, gastrointestinal 
hemorrhage, bacterial infection or any combination of these warranting 
hospital admission[3]. The enrolled patients were followed for 90 days or until 
death. Presence and grade of organ system failure(s) [OF] were determined 
retrospectively based on the available clinical and laboratory data after 
accessibility of CLIF-C Organ Failure Score[30].  
The diagnosis of bacterial infection was established by assessment of 
clinical symptoms and laboratory reports, including microbiological culture 
results (if available), compatible findings of imaging techniques, and the effect 
of antibiotic treatment by two independent gastroenterologists (M.P. and 
Zs.V.). Following bacterial infections were considered and diagnosed on the 
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basis of conventional criteria: 1. skin and soft tissue infections[31]; 2. lower 
respiratory tract infections (acute bronchitis, pneumonia)[32]; 3. urinary tract 
infections (UTI) (cystitis, pyelonephritis)[33]; 4. some rare causes of infections, 
such as biliary tract infections (cholecystitis, cholangitis, liver abscess), 
osteomyelitis, and endocarditis; 5. spontaneous bacterial peritonitis (SBP), 
diagnosis of which was based on ascitic fluid polymorphonuclear cell (PMN) 
count exceeding 250/mm3 and/or positive culture if secondary causes of 
peritonitis were excluded (EASL guidelines[34]); 6. bacterial infection of 
unknown origin defined when clinical symptoms and signs of infection were 
present and confirmed by microbiological demonstration of the causative 
organism from blood culture in the absence of site-specific infection. Bacterial 
infection was considered severe when the infectious episode was complicated 
by OF. 
 
Measurements of presepsin and other laboratory parameters 
Venous blood samples were captured at enrolment. Routine laboratory data, 
such as liver biochemistry, renal function, blood count and serum CRP and 
PCT levels were determined directly at the Department of Laboratory 
Medicine. Methods for qualitative assessment of serum CRP and PCT levels 
were reported previously[9]. 
For presepsin measurements, blood samples were immediately 
centrifuged at 3000g for 10 minutes, and plasma was stored at -70 °C until 
use. Presepsin levels were measured by means of a PATHFAST® presepsin 
analyzer (Mitsubishi Chemical Medience Corporation, Tokyo, Japan) which is 
based on chemiluminescent enzyme immunoassay, with a detection limit of 
20 pg/mL.  
 
Outcome 
For outcome assessment, a follow-up examination was set up at the 28th day 
after enrolment in the study. Patients who survived until follow-up were 
counted as survivors, whereas patients who died within the follow-up period 
were counted as non-survivors.  
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Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous 
variables were summarized as means [standard deviation (SD)] or as medians 
[interquartile range (IQR)] according to their homogeneity. Categorical 
variables were compared with the χ2-test or χ2-test with Yates correction as 
appropriate. Continuous variables were compared with the Mann–Whitney U 
test or Student’s t test. Relationship between continuous variables was 
assessed with the non-parametric Spearman correlation. Diagnostic accuracy 
of presepsin and other APPs for defining various study-endpoints: (1) 
presence of bacterial infection (2) presence of severe infection, and (3) short-
term mortality was estimated using receiver operating curve (ROC) analysis 
by plotting sensitivity vs. 1-specificity. Area under the curve (AUC-ROC) and 
corresponding 95% confidence intervals (CI) were calculated. ROC curves 
were compared with the method of DeLong et al. in Medcalc[35]. Youden index 
was chosen, calculated as the maximum (sensitivity+specificity-1) value, to 
estimate the best discriminate thresholds. Sensitivities, specificities, positive 
predictive values (PPV) and negative predictive values (NPV) were calculated 
to determine the predictive power of individual APPs or their combinations 
in all the three clinical settings. Binary logistic regression was used to assess 
the relationship between APPs and short-term mortality adjusted for the 
MELD score and WBC count. For the analysis APPs were loge-transformed to 
ensure normal distribution. Associations are given as odds ratios (OR) or 
likelihood ratios (LR) with a 95% CI. A 2-sided probability value <0.05 was 
considered to be significant. For statistical analysis and graphical presentation 
SPSS 22.0 (SPSS Inc., Chicago, IL, US) and GraphPad Prism 7 (San Diego, 
CA, US) were used. 
 The statistical methods of this study were reviewed by Professor Elek 
Dinya, PhD, DSc, Semmelweis University, Institute of Health Informatics, 
Budapest, Hungary. 
 
Review of the literature 
We performed a systematic review of studies reporting on CRP and PCT in 
Papp M Presepsin in cirrhosis 12 
prognosis of cirrhosis. Papers were eligible if they presented original research 
in adult patients with cirrhosis and reported association of CRP and/ or PCT 
to the disease outcome either in patients with or without bacterial infection. 
Studies had to have been published in peer-reviewed journals. We started 
searching PubMed using the following search terms: [“C-reactive protein” OR 
“procalcitonin”] AND “liver cirrhosis”. Limits were human and time ranging 
from 1991 until 2016 (1st June). Only article reported short or long-term 
outcome in cirrhosis were included. This search revealed 20 articles. In Table 
6 we summarizes the clinical significance of CRP and PCT in the prediction of 
disease course in cirrhosis based on findings in relevant literature. 
 
Ethical permission 
All patients were informed of the nature of the study and signed an 
informed consent form. The regional and national committee (DEOEC 
RKEB/IKEB 5306-9/ 2011, 3885/2012/EKU [60/PI/2012]) for research ethics 




Study population  
Two hundred and sixteen patients with cirrhosis were enrolled in this cohort. 
The main characteristics of patients with or without infection are summarized 
in Table 1. There were 118 men with a mean age of 57.6±10.3 years. The 
median Child-Pugh and MELD score were 7 (95%CI: 6-9) and 13 (95%CI: 10-
17), respectively. The main baseline characteristics were as follows: alcoholic 
liver disease in 159 patients (73.6%), HCC in 15 patients (6.9%) and renal 
impairment in 33 (15.3%) based on creatinine cut-off values ≥133 µmol/L. 
One-hundred and seventeen patients (54.2%) had extrahepatic co-morbidities. 
Acute decompensation of the disease warranting hospital admission occurred 
in a total of 101 patients (46.8%) of whom 27 (26.7%) had at least one OF.  
Documented bacterial infection was present in 75 (34.7%) patients of 
whom 9 (12.0%) suffered from multifocal episode. Bacteria were Gram-
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negative in 52.6% and Gram-positive in 47.4% of culture-positive cases. No 
cases of invasive fungal infections were detected. The distribution of 
infections is shown in Table 1. The infected and the non-infected patient 
groups did not differ in gender, age, and presence of comorbidities. However, 
patients with infections had more advanced disease stage, as indicated by 
median values of Child-Pugh and MELD score and presence of ascites. Renal 
impairment (29.3% vs. 7.8%, p<0.001) and occurrence of HCC (14.7% vs. 2.8%, 
p=0.003) were more frequent in patients with infection as compared to those 
without as well. The occurrence of AD episodes and the development of OF 
were more common in the presence of infections (AD INF vs. NON-INF: 85.3% vs. 
26.2%, p < 0.001 and OF INF vs. NON-INF: 37.5% vs. 8.1%, p=0.001).  
 
Association between presepsin levels and bacterial infections 
Presepsin values ranged from 142 to 5950 pg/mL (median [IQR], 576 pg/mL 
[376–972]) and were significantly higher in patients with infection as 
compared to those without (1002 pg/mL [575-2149] vs. 477 [332-680] pg/mL, 
p<0.001) (Figure 1). This association was also confirmed in the different 
disease severity subgroups according to Child-Pugh stage (Figure 2A) or the 
presence of ascites (Figure 2B). In the subgroup of patients with renal failure, 
presepsin levels were also different numerically between infected and non-
infected patient groups however it did not reach statistically significance 
(p=0.08) (Figure 2C). Further evaluating non-infected patients, a significant 
increase was observed in presepsin levels in case of more advanced disease 
stage and also in the presence of renal failure (p<0.001 for both). 
Presepsin level was positively correlated with classic markers of 
bacterial infections, such as CRP, PCT, and different WBC parameters, but 
also with renal and liver function tests (Table 2) and accordingly with liver 
liver-oriented scores (CPs and MELD). 
Considering the type of infectious episodes, presepsin level was not 
different according to the location or Gram specificity of the infection (data 
not shown). Patients with multifocal infections (10.6%) showed numerically 
higher presepsin levels than those with unifocal ones without reaching 
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statistically significance (2470 pg/mL [729-2671] vs. 983 pg/mL [560-1774], 
p=0.065). Nonetheless, presepsin level was associated with the severity of the 
infection. Twenty-four infections (32%) were complicated with at least one 
OF. Presepsin level was significantly higher in patients with OF as compared 
to those without (2358 pg/mL [1398-3666] vs. 710 pg/mL [533-1277], p<0.001) 
(Figure 1). 
 
Accuracy of presepsin level in the diagnosis of bacterial infections 
compared to classic acute phase proteins 
The diagnostic accuracy of presepsin for identifying patients with infection 
was established by ROC analysis and compared to CRP and PCT. Presepsin 
was similar predictor of bacterial infection in overall (AUC-ROC, [95%CI]: 
0.79 [0.73-0.84]) compared to PCT (0.77 [0.71-0.83], p=0.668) but somewhat 
lower than CRP (0.86 [0.80-0.90], p=0.057) (Figure 3A). Combination of CRP 
with presepsin, however, increased the sensitivity and NPV, compared with 
CRP on its own, by 9 % and 4 % respectively. A similar trend was found with 
the combination of CRP and PCT (Table 3). On the contrary, the diagnostic 
accuracy of presepsin (AUC-ROC [95%CI]: 0.85 [0.74-0.92]) for identifying 
patients with infection complicated by OF was similar to PCT (0.85 [0.74-
0.92]) and clearly superior to CRP (0.66 [0.54-0.77]; p=0.994 for presepsin vs. 
PCT, and p<0.01 for both presepsin vs. CRP and PCT vs. CRP) (Figure 3B). 
The optimum diagnostic thresholds for each individual biomarker based on 
ROC analysis and their performances belonging to the cut-off points are 
shown in Table 3.  
 
Diagnostic accuracy of presepsin level according to the disease severity  
Diagnostic accuracy of presepsin for identifying patients with infection 
decreased in advanced stage of the disease and also in the presence of renal 
failure. Specificity and LR values of presepsin >844 pg/mL were obviously 
lower in patients with Child B or C stage cirrhosis (74%; LR+: 2.28, LR-: 0.56) 
compared with those with Child A (96%; LR+: 15.6, LR-: 0.31), whereas the 
difference in sensitivity was somewhat less (70% vs. 58%). A similar trend 
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was found when the performance of presepsin >844 pg/mL was evaluated in 
patients with or without renal failure (specificity: 46% vs. 87%; sensitivity: 
86% vs. 49%; LR+: 1.58 vs. 3.86, LR-: 0.30 vs. 0.58, respectively).  
 
Association of presepsin level with short-term mortality during infectious 
episodes 
Seventy-five patients with bacterial infection were eligible for evaluation of 
short-term mortality. Twenty-three patients (31.5%) died within 3 months of 
follow-up. Of these, 20 patients (27.4%) died within the first 28 days. Plasma 
presepsin levels at admission were significantly higher in non-survivors than 
in survivors at the 28-day follow-up (2323 [1172-3688] vs. 852 [549-1451] 
pg/mL, p<0.001). Discriminative ability (AUC-ROC) of presepsin was 0.76 
with the best cut-off value of 1277 pg/mL. 28-day mortality rate was 
significantly higher among patients with presepsin level above this threshold 
(46.9% vs. 11.6%, p<0.001). The optimum cut-off values and the belonging 
sensitivities, specificities, PPVs and NPVs of all three APPs for identifying 
non-survivors are summarized in Table 4.  
  In the univariate logistic regression analysis, increased presepsin level 
was found to be a risk factor of short-term mortality during bacterial infection 
[OR: 3.59 (95%CI: 1.65–7.84), p=0.001] similarly to CRP and PCT. Presepsin 
level however lost it significance after adjusting for MELD score and 
leukocyte count [OR: 1.61, (95%CI: 0.65–3.97), p=0.303], with multivariate 
binary logistic regression analysis. PCT was the only APP that was 
independently associated with the risk of short-term mortality [OR: 1.81, 




 Infected patients with cirrhosis can be asymptomatic at initial stages, 
but highly susceptible to dissemination of infections due to their 
immunocompromised state that leads to development of severe disease 
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specific complications with significant mortality rate[36,37]. Accurate laboratory 
markers are of importance to maximize the efficacy of diagnostic procedure of 
bacterial infections and thus making possible early intervention. C-reactive 
protein is the most widely used APP in the everyday clinical practice; 
however, it has some limitations in patients with cirrhosis[5]. Thus 
identification of novel biomarkers is required to reach this unmet need in this 
patient group. 
Primary aim of our study was to assess the performance of presepsin – 
a recently reported novel sepsis marker – in the diagnosis of cirrhosis 
associated bacterial infections in comparison with routinely used APPs (CRP, 
PCT) in such a patient cohort that represents the everyday clinical practice. To 
the best of our knowledge, this is the first study in cirrhosis, reporting the 
feasibility and the usefulness of presepsin in these clinical settings. We 
evaluated a large cohort of patients, in which not only severe but also mild 
forms of the infections were represented. One-third of patients had mild 
infections and mainly localized to the urinary tract, while another subgroup 
of patients (32%) suffered in severe infectious episodes. In our study severe 
infectious episodes were defined by the presence of hepatic and/or 
extrahepatic OF(s), since currently accepted clinical definition of SIRS and 
hence sepsis[38] is not entirely applicable to cirrhotic patients for various 
reasons[5]. New definition of OFs has directly been elaborated for cirrhotic 
patient population recently[3,30] that use simple measures and is easy to apply 
in everyday clinical practice. Moreover presence of OF is predictive of worse 
outcome[2].  
For the diagnosis of bacterial infections, the best cut-off level of 
presepsin was 844 pg/mL in our cirrhotic patient cohort. Diagnostic cut-off 
levels were different in previous studies in non-cirrhotic populations, but 
most reports suggest an approximate level of 400–600 pg/mL[39,40].  
Presepsin alone was not suitable as a screening tool to search for 
infection, however adding it to CRP, we found that presepsin was clinically 
useful. For the first, this combination amended efficacy of identification of the 
infectious episode. Sensitivity and NPV were increased by 9% and 4% 
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compared to CRP alone. Secondly, presepsin was able to distinguish severe 
infectious episode from non-severe ones more properly compared to CRP; 
AUC-ROC values were 0.85 and 0.66, respectively. Performance of presepsin 
corresponds to those reported in non-cirrhotic septic patient populations. In a 
recent meta-analysis of Zheng et al.[41], comprising a total of 8 studies and 1757 
patients, the AUC of the summary ROC (SROC) was 0.82. In contrast, weak 
predictive power of CRP with an AUC-ROC of 0.64 was reported for the 
infections in critically ill patients with cirrhosis in intensive care unit (ICU) 
[22], which is also in agreement with our results. Regarding CRP, patients with 
cirrhosis may present reduced CRP in response to infection[5,10].  
It is acknowledged, that level of certain APPs are different according to 
the pathogens causing infections, while others are not. In a landmark study of 
Angeletti S et al. level of PCT and mid-regional pro-adrenomedullin (MR-
proADM) were found to be significantly higher in patients with sepsis caused 
by Gram-negative than Gram-positive strains[42]. These data are also 
confirmed by other studies[43–45]. Some reports also highlighted differences in 
circulating cytokine levels in bloodstream infections according to Gram 
specificity, i.e. Gram-negative infections leaded to higher increase in the level 
of interleukin (IL)-6, TNF-alpha or IL-10[46]. On the contrary, levels of other 
APPs, such as C-reactive protein, soluble (s)CD14, sCD163 or soluble 
urokinase plasminogen activator receptor (SuPAR) are not in relation with the 
Gram specificity of the infection[47–50]. In the present study, presepsin level 
was not different according to Gram specificity of the infection, which is in 
agreement with previous literature findings[51–53]. 
Overall, presepsin was indisputably a valuable complementary tool in 
our cirrhotic patient cohort from a clinical point-of-view, but cost issues might 
compromise their joint use in the laboratory screening procedure of 
infections. Adding presepsin to CRP increased significantly the cost, from 0.9 
to 12.5 $. Medico-economic evaluation, however is lacking by this time and 
should be performed before proposing introduction of their combined use 
into routine clinical practice. Presepsin had very similar discriminative ability 
as PCT in both above-mentioned clinical settings. Furthermore, prices of 
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presepsin and PCT are also comparable (12.5 and 10.7 $) suggesting their 
interchangeability in this patient population.  
 Secondary aim of our study was to evaluate whether presepsin is 
devoid of the limitations of classic APPs in cirrhosis. Previously in a small 
case-control study of Park et al.[10] showed that the more severe the underlying 
liver dysfunction, the lower the CRP response to bacteremia was. Equally in a 
former study[9] we reported that the diagnostic accuracy of both CRP and PCT 
for identifying patients with infection obviously decreased in advanced stage 
of the disease or in presence of ascites. Correspondingly, presepsin behaved 
alike in the present study. Presepsin is not primarily synthesized in the liver, 
thus not the decreasing synthetic capacity is the major limitation of their 
diagnostic performance in advanced cirrhosis. Ongoing chronic inflammatory 
state is a characteristic feature of cirrhosis that is potentially able to induce the 
synthesis of APPs in the absence of infection[54,55] and inevitably limits their 
clinical utility in the diagnostic procedure of bacterial infections. Out of 
various explanations, BT has major importance. Bacterial translocation is 
frequently reported in patients with cirrhosis-associated severe liver 
dysfunction or ascites[56,57]. It is likely that this process resulted in higher 
presepsin level in our non-infected cirrhotic patients compared to healthy 
controls in previous studies[39,58]. Furthermore, presepsin levels were 
associated with diseases severity (Child A: 361, Child B: 530 and Child C: 703 
pg/mL, p< 0.001) or presence of ascites (Yes vs. No: 382 and 575 pg/mL, p< 
0.001) in the non-infected patient group as well. 
 Another important, but rarely considered issue is the effect of renal 
function on the levels of APPs. Acute kidney injury (AKI) is a frequent 
complication of cirrhosis, occurring in up to 50% of hospitalized patients with 
cirrhosis[59]. Exact clearance mechanism of presepsin is unknown but 
considering its low MW it is presumably filtered by the glomeruli, 
reabsorbed, and catabolized within the proximal tubular cells[60]. From a 
clinical point of view, little information is available on the accurate association 
between presepsin level and kidney function. Nagata et al.[61] reported that 
presepsin levels tend to increase with decreasing glomerular filtration rate – 
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assessed by inulin renal clearance measurements – and are markedly high in 
patients with chronic renal failure or receiving hemodialysis. Nakamura et 
al.[62] retrospectively analyzed presepsin levels in patients with or without 
sepsis presenting in the ICU, and found that presepsin levels were markedly 
high in patients with renal failure and end-stage kidney disease. Accordingly, 
we evaluated the impact of kidney function on presepsin levels. Significant 
correlation was found between presepsin and serum creatinine level 
(Spearman’s rho:  +0.36, p< 0.001). Furthermore, in a small subgroup of 
patients with renal failure, presepsin values were markedly high even in the 
absence of infection, at comparable levels to those of bacterial infection but 
without renal failure (1011 vs. 774 pg/mL). These results suggest that the 
evaluation of presepsin levels in cirrhosis warrants special consideration 
during AD episodes complicated by AKI, and probably a different cut-off is 
needed for diagnosing infection in such patients. 
 Third aim of our study was to assess whether presepsin is able to 
provide prognostic information in cirrhosis associated bacterial infections. 
Studies in this clinical setting only exist regarding CRP[19,20,63–75] and PCT[76–80] 
and their findings are not without controversies. In Table 6 we summarized 
available data on clinical significance of CRP and PCT in short or long-term 
mortality of patients with cirrhosis. Most of the studies included both stable 
outpatients and patients with ongoing AD episodes with or without bacterial 
infections. Furthermore, evaluations often were done as a whole of these non-
homogenous patient groups rendering direct comparison and single 
conclusion rather difficult. Recently, an important concept has been derived 
from the CANONIC study[3]. Acute-on-chronic liver failure (ACLF) is 
associated with systemic inflammation and robust inflammatory response as 
judged by presence of elevated CRP or elevated leukocyte count results in 
worse outcome. Higher leukocyte count was found to be an independent 
predictor of 28-day transplant-free mortality. Based on these it was reasonable 
to assume that excessive increase in the APP levels, as a representative of the 
exaggerated inflammatory process could be associated with higher risk of 
short-term mortality in cirrhosis during bacterial infections. In patients with 
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increased level of PCT, CRP and presepsin, short-term mortality was 
significantly higher. Indeed, higher level of PCT, CRP and presepsin were 
associated with short-term mortality in our study. However, after adjusting 
for diseases severity and leukocyte count, this association was only preserved 
for PCT and not for CRP or presepsin. From biological point of view this 
finding might be explained by the fact that presepsin has a different profile. It 
belongs to a distinctive class of molecules, so-called “hormonkines”[81]. 
Procalcitonin has a cytokine-like behaviour during inflammation and 
infection. It is produced primarily in neuroendocrine cells of various organs 
and represents involvement of several instead of one organ into the pro-
inflammatory response[82]. Lastly, it has been demonstrated that PCT has 
various toxic effects and pose harm to the host. Administration of PCT to 
septic animals greatly increases mortality. Antibodies directed against PCT 
are able to ameliorate harmful effects of PCT with a marked decrease 
symptomatology and mortality of sepsis[83]. Presepsin represents activation of 
the monocyte-macrophage system during inflammatory process. 
Macrophages have a dual effect: production of excessive amount of 
inflammatory cytokines can cause tissue damage but involvement in the 
resolution of the inflammation promote tissue repair. This latter process is 
driven by M2-type macrophages in the presence of local microenvironmental 
anti-inflammatory signals such as IL-10[84]. 
 Plasma presepsin was only assessed at enrolment, and thus dynamic 
changes of the concentration were unknown, which is inevitably one of the 
limitations of the present study. For this reason, clinical study will be needed 
to further investigate serial changes in presepsin levels and their possible 
association with worse outcome during infection.  
 To conclude, the present study suggests that presepsin is a promising 
biomarker during diagnostic procedure of bacterial infections in cirrhosis for 
enhancing diagnostic capacity of CRP and reflecting more accurately the 
severity of infections. Performance of presepsin is equal to PCT in these 
clinical settings. Diagnostic accuracy of presepsin, however, decreases in 
advanced stage of the disease or in the presence of renal failure. Level of 
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presepsin is not associated with the pathogens causing infections. 
Procalcitonin but not presepsin is a biomarker for predicting infection-related 
short-term mortality in patients with cirrhosis. 
 
COMMENTS 
 (1) Background 
Bacterial infections are frequent complications in cirrhosis and often 
culminate in newly developed liver and/or extrahepatic organ failures, which 
is associated with significant mortality. Early laboratory diagnosis of these 
episodes is essential but challenging. There is an evident lack of sensitivity 
and specificity of the conventional laboratory markers due to disease specific 
characteristics. Advanced stage of cirrhosis affects diagnostic accuracy of liver 
synthesised acute phase proteins (e.g. C-reactive protein) whereas acute 
kidney injury affects renal clearance of small molecules (e.g. procalcitonin). 
Enhanced bacterial translocation induces significant elevation of 
inflammatory markers as well. Additional biomarkers are highly needed to 
optimize the diagnostic procedure and severity assessment of the infectious 
episodes in cirrhosis. Presepsin is a novel biomarker of activated monocyte-
macrophage in response to pathogens and specific and sensitive marker of the 
sepsis.  
 
 (2) Research frontiers 
Presepsin is worthy of studying in cirrhosis, where systemic infections are 
frequently associated with severe diseases course, such as acute development 
of liver and/or extrahepatic organ failures. Contributive role of presepsin for 
the diagnosis and prognosis of cirrhosis associated bacterial infection, 
however, has not been assessed extensively so far.  
 
(3) Innovations and breakthroughs 
To our knowledge, this is the first study in cirrhosis to investigate the 
performance of presepsin in the diagnosis and prognosis of cirrhosis 
associated bacterial infections. Presepsin is a promising biomarker of infection 
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in terms of diagnostic but not the prognostic procedure. Presepsin enhances 
diagnostic capacity of C-reactive protein and reflects more accurately severity 
of infections. In these clinical settings its performance is equal to 
procalcitonin. Diagnostic accuracy of presepsin, however, decreases in 
advanced stage of the disease or in the presence of renal failure. Level of 
presepsin is not associated to the pathogens causing infections.  
 A clear strength of our study is the large study population that 
represents the everyday clinical practice and assessment of presepsin in 
comparison with routinely used acute phase proteins. We also provide a 
profound overview about the significance of routinely used acute phase 
proteins in the prognosis of cirrhosis. 
 
(4) Applications 
In every day clinical practice, presepsin is a useful complementary adjunct to 
C-reactive protein and promising alternate of procalcitonin during the 
diagnostic procedure of cirrhosis associated bacterial infection. However, it is 
not devoid of the limitations of these classic acute phase proteins in the 
presence of advanced stage or certain acute complications of the disease. 
Larger prospective studies including serial changes in presepsin levels are 
needed to further investigate any possible association of presepsin level with 
worse outcome during infection or any suggestion for more aggressive or pre-
emptive antibiotic therapy according to presepsin level. 
 
(5) Terminology 
Presepsin or soluble CD14 subtype (sCD14-ST) is a 13-kDa-cleavage product 
of CD14 receptor of monocyte-macrophage that recognizes different cell 
surface structure of both Gram-negative and positive bacteria. Bacterial 
translocation is defined as an enhanced passage of bacteria and/or bacterial 
products from the intestinal tract to systemic circulation.  
 
Peer-review 
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This study suggests for the first time that presepsin is a promising biomarker 
during diagnostic procedure of bacterial infections in cirrhosis for enhancing 
diagnostic capacity of C-reactive protein and reflecting more accurately the 
severity of infections. Performance of presepsin is equal to procalcitonin in 
these clinical settings. Distinctly to procalcitonin and certain cytokines, 
presepsin level is not associated to the pathogens causing infections. 
Moreover, procalcitonin but not presepsin is a biomarker for predicting 
infection-related short-term mortality in patients with cirrhosis. Acute phase 
proteins are not simply surrogate markers of on-going inflammatory 
processes of the host organism but might also be active participants, hence 
exerting harmful or beneficial effects. 
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TABLES 
Table 1. Demographic, clinical and laboratory characteristics of patients 
with or without bacterial infections 
 
Non-Infected Infected P-value 
N 141 75 
 Gender (male/female) 77/64 41/34 N.S 
Age (years) 57.3 ± 10.7 58.1 ± 9.7 N.S 
Child-Pugh score  6.9 ± 1.7 9.3 ± 2.2 < 0.001 
Child-Pugh stage 
   A 58 (41.1%) 6 (8.0%) 
< 0.001 
B 65 (46.1%) 28 (37.3%) 
C 18 (12.8%) 41 (54.7%) 
MELD score 12.3 ± 4.1 19.1 ± 9.1 < 0.001 
Serum bilirubin (µmol/L) 41.4 ± 38.3 124.1 ± 147.4 < 0.001 
Serum albumin (g/L) 35.4 ± 7.1 28.1 ± 6.5 < 0.001 
INR 1.3 ± 0.2 1.6 ± 0.5 < 0.001 
Serum creatinine (µmol/L) 83.8 ± 74.3 131.2 ± 129.9 < 0.001 
Ascites present 58 (41.1%) 59 (78.7%) < 0.001 
HCC 4 (2.8%) 11 (14.7%) = 0.003 
Comorbidities present 72 (51.1%) 45 (60.0%) N.S 
Type of bacterial infections 


















 Acute phase proteins,  
median [IQR] 
   
Presepsin 
(pg/mL)  








[1398-3666] < 0.001 
CRP 
(mg/L) 



















[0.6-5.3] < 0.001 
 
Data are presented as mean ± SD or n (%) if not otherwise indicated 
CRP: C-reactive protein, HCC: hepatocellular carcinoma, IQR: interquartile 
range, INR: international normalized ratio, MELD: model for end-stage liver 
disease score, N.S.: non-significant, PCT: procalcitonin, SD: standard 
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deviation, UTI: urinary tract infection, SBP: spontaneous bacterial peritonitis, 
SSTI: skin and soft tissue infection 
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Table 2. Correlations between presepsin and different laboratory 





CRP +0.63 < 0.001 
PCT +0.53 < 0.001 




+0.36 < 0.001 
 
Serum bilirubin +0.28 < 0.001 
Serum albumin -0.40 < 0.001 
INR +0.15 0.032 
 
CPs +0.42 < 0.001 
MELD score +0.45 < 0.001 
CRP, C-reactive protein; CPs, Child-Pugh score; INR, international 
normalized ratio; MELD score, model for end-stage liver disease; PCT, 
procalcitonin  
